Erasca, Inc.

Erasca, Inc. reported a net loss of $44.1 million for the second quarter of 2026 and $227.5 million for the six months ended June 30, 2026, significantly higher than the prior year due to increased operating expenses, including a $150 million in-process research and development expense. Following the quarter, the company completed an underwritten offering in July 2026, raising $593.5 million in net proceeds. This capital infusion is expected to fund operations for at least one year, despite the accumulated deficit reaching $1.12 billion.

Erasca, Inc. reported a net loss of $44.1 million, or $(0.14) per share, for the second quarter ended June 30, 2026, compared to a net loss of $33.9 million, or $(0.12) per share, for the same period in 2025. The company's cash, cash equivalents, and marketable securities stood at $384.3 million as of June 30, 2026. Erasca also announced the completion of an upsized public offering in July 2026, which raised approximately $632.5 million in gross proceeds, significantly strengthening its balance sheet. Additionally, updated clinical data for ERAS-0015 highlighted compelling monotherapy efficacy in pancreatic cancer and favorable tolerability, with the program advancing toward three potentially registration-enabling trials. Preliminary Phase 1 monotherapy data for ERAS-4001 is anticipated in the second half of 2026.

Erasca, Inc. reported updated clinical data for ERAS-0015, highlighting compelling monotherapy efficacy in 2L+ KRAS G12X pancreatic ductal adenocarcinoma and favorable tolerability. The company plans to advance ERAS-0015 toward three potentially registration-enabling trials in pancreatic and lung cancers. Erasca also announced a successful upsized public offering in July 2026, raising $632.5 million, significantly strengthening its balance sheet. For Q2 2026, the company reported a net loss of $44.1 million and R&D expenses of $35.9 million.

Erasca, Inc. announced the appointment of Charles S. Fuchs, M.D., M.P.H., as its new president of research and development. In connection with his appointment, Dr. Fuchs was granted inducement awards consisting of non-qualified stock options to purchase 1,278,520 shares of Erasca common stock. These options will vest over time, with an initial 25% vesting on August 10, 2027, and the remainder vesting monthly thereafter.

Erasca, Inc. announced the successful closing of its previously announced upsized public offering, raising approximately $632.5 million in gross proceeds. The company sold 36,142,857 shares of its common stock at a price of $17.50 per share, which included the full exercise of the underwriters' option to purchase additional shares. Erasca plans to utilize the net proceeds from this offering, combined with its existing cash, to fund the research and development of its product candidates and for general corporate purposes.

Erasca, Inc. announced the pricing of an upsized public offering of 31,428,572 shares of its common stock at $17.50 per share, expecting gross proceeds of approximately $550.0 million. The underwriters also have a 30-day option to purchase up to an additional 4,714,285 shares. Net proceeds are anticipated to be around $516.0 million, or $593.5 million if the option is fully exercised, which will be used to fund research and development of product candidates and for general corporate purposes. The offering is slated to close on July 15, 2026.

Erasca, Inc. announced the pricing of an upsized public offering of 31,428,572 shares of its common stock at $17.50 per share. The offering is expected to generate gross proceeds of approximately $550.0 million for the company. Erasca has also granted underwriters an option to purchase up to an additional 4,714,285 shares. The net proceeds from this offering will be used to fund research and development of its product candidates and for general corporate purposes.

Erasca announced updated preliminary Phase 1 data for its pan-RAS molecular glue ERAS-0015 from the AURORAS-1 trial. The drug demonstrated encouraging monotherapy responses with a 57% uORR8wk in patients with 2L+ KRAS G12X pancreatic ductal adenocarcinoma and continued to be generally well-tolerated. The company also reported promising combination potential with panitumumab and is accelerating its potentially registration-enabling development plans for NSCLC and PDAC, with trials expected to begin in 2027 and early 2028.

Erasca, Inc. announced its intention to offer and sell $500.0 million of shares of its common stock in a proposed underwritten public offering. The company also plans to grant the underwriters a 30-day option to purchase up to an additional $75.0 million of common stock. Proceeds from the offering, combined with existing cash, will be used to fund research and development of its product candidates, other development programs, and for general corporate purposes. J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI are acting as joint book-running managers for the offering.

Erasca, Inc. announced updated preliminary Phase 1 data for its pan-RAS molecular glue ERAS-0015, showing encouraging monotherapy responses with a 57% unconfirmed Overall Response Rate (uORR) in 2L+ KRAS G12X pancreatic cancer. The drug was generally well-tolerated, and promising combination potential with panitumumab was observed. Based on these results, Erasca plans to accelerate development, initiating a potentially registration-enabling trial in lung cancer in H1 2027, a Phase 3 trial in pancreatic cancer in 2027, and another Phase 3 trial in lung cancer in H2 2027 to H1 2028.